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Objectives The purpose of this study was to determine whether a new accelerated diagnostic protocol (ADP) for possible cardiac
chest pain could identify low-risk patients suitable for early discharge (with follow-up shortly after discharge).
Background Patients presenting with possible acute coronary syndrome (ACS), who have a low short-term risk of adverse
cardiac events may be suitable for early discharge and shorter hospital stays.
Methods This prospective observational study tested an ADP that included pre-test probability scoring by the Thrombolysis
In Myocardial Infarction (TIMI) score, electrocardiography, and 0  2 h values of laboratory troponin I as the sole
biomarker. Patients presenting with chest pain due to suspected ACS were included. The primary endpoint was
major adverse cardiac event (MACE) within 30 days.
Results Of 1,975 patients, 302 (15.3%) had a MACE. The ADP classified 392 patients (20%) as low risk. One (0.25%) of these pa-
tients had a MACE, giving the ADP a sensitivity of 99.7% (95% confidence interval [CI]: 98.1% to 99.9%), negative predictive
value of 99.7% (95% CI: 98.6% to 100.0%), specificity of 23.4% (95% CI: 21.4% to 25.4%), and positive predictive value of
19.0% (95% CI: 17.2% to 21.0%). Many ADP negative patients had further investigations (74.1%), and therapeutic (18.3%)
or procedural (2.0%) interventions during the initial hospital attendance and/or 30-day follow-up.
Conclusions Using the ADP, a large group of patients was successfully identified as at low short-term risk of a MACE and therefore
suitable for rapid discharge from the emergency department with early follow-up. This approach could decrease the
observation period required for some patients with chest pain. (An observational study of the diagnostic utility of an accel-
erated diagnostic protocol using contemporary central laboratory cardiac troponin in the assessment of patients presenting
to two Australasian hospitals with chest pain of possible cardiac origin; ACTRN12611001069943) (J Am Coll Cardiol
2012;59:2091–8) © 2012 by the American College of Cardiology Foundation
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Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8A missed diagnosis of acute coro-
nary syndrome (ACS) may lead to
further ischemic events and a poten-
tially preventable death or disability.
Therefore, patients with symptoms
suggestive of ACS often undergo a
lengthy assessment in the emer-
gency department (ED) or as hospi-
tal inpatients. These patients ac-
count for approximately 10% of ED
See page 2099
presentations and 25% of hospital
admissions (1), yet up to 85% do not
have a final diagnosis of ACS (2–4).
Prolonged assessment contributes to
duplication of work, high costs, and
ED overcrowding, which leads to
adverse patient outcomes, including
increased mortality (1,5). The need
for accurate identification of a low-
risk group that may be safely dis-
charged without jeopardy of an adverse event from an ACS is
therefore a priority (4).
International guidelines for the investigation of ACS rec-
ommend serial measurement of cardiac troponin (cTn) at the
onset of symptoms, and many hospitals use the presentation
at the ED as time zero for sampling (6–10). A reproducible,
reliable, and more timely process for identifying patients
presenting with chest pain who have a low short-term risk
of adverse cardiac events is needed to support their earlier
discharge (4). Only 2 studies have prospectively validated
accelerated diagnostic protocols (ADPs) for the early dis-
charge of low-risk patients using serial biomarkers in the
first 2 hours after arrival (11,12).
The recent ASPECT (A 2-h Diagnostic Protocol to
Assess Patients with Chest Pain Symptoms in the Asia-
Pacific region) study used 0- and 2-h biomarker testing with
a point-of-care multimarker panel, electrocardiography
(ECG), and the Thrombolysis In Myocardial Infarction
(TIMI) score (11). In that study, the ADP identified 9.8%
of patients with suspected ACS who could have been
discharged early from the ED, with a sensitivity of 99.3%
for 30-day major adverse cardiac events (MACE).
Some studies have shown superiority of point-of-care mul-
timarker strategies compared with troponin alone when used
for early evaluation of such patients, but studies have been
criticized for using relatively insensitive cTn assays. Current
laboratory troponins may now be equivalent or superior to point-
of-care multimarker strategies even at these early time points (13).
This might increase the number of patients eligible for early
discharge, while maintaining very high sensitivity (99%).
The purpose of this study was to determine if an ADP
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
ADP  accelerated
diagnostic protocol
AMI  acute myocardial
infarction
cTn  cardiac troponin
cTnI  cardiac troponin I
ECG  electrocardiography
ED  emergency
department
HS-cTn  highly sensitive
cardiac troponin
MACE  major adverse
cardiac event(s)
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionusing a serial troponin as the only biomarker could identify 0ED patients suspected of having ACS who are suitable for
safe early discharge. These patients could then have early
outpatient or accelerated in-patient follow-up.
Methods
Study design and setting. The ADAPT (2-Hour Accel-
erated Diagnostic Protocol to Assess Patients With Chest
Pain Symptoms Using Contemporary Troponins as the
Only Biomarker) trial was a prospective observational vali-
dation study designed to assess a predefined ADP that
consisted of TIMI score risk assessment, ECG, and 0- and
2-h central laboratory contemporary cardiac troponin I
(cTnI) as the only biomarker. The study population was
from the Brisbane, Australia and Christchurch, New Zea-
land, that is, 2 of the 14 sites participating in the ASPECT
study. Most participants were recruited as part of the
ASPECT trial, but we also included additional patients
through ongoing post-ASPECT recruitment at both cen-
ters. The process for 2-h blood sampling and central
laboratory analysis of cTnI was pre-planned before the start
of the ASPECT study, and a priori local ethics committee
approval was obtained for this. All participants provided
written informed consent. The results of the 2-h cTnI
samples were not used as part of routine clinical care (or for
reference standard adjudication). This study was subse-
quently separately registered with the Australia-New Zea-
land Clinical Trials Registry, ACTRN12611001069943.
Participants. Patients were enrolled consecutively between
November 2007 and February 2011, at 2 urban EDs in
Brisbane, Australia and in Christchurch, New Zealand. Due
to local recruitment logistics, enrollment did not start and
finish at the same time in each center. Criteria for enroll-
ment included age 18 years of age, with at least 5 min of
symptoms consistent with ACS, where the attending phy-
sician planned to perform serial cTn tests. The American
Heart Association case definitions for possible cardiac
symptoms were used (i.e., acute chest, epigastric, neck, jaw,
or arm pain; or discomfort or pressure without an apparent
noncardiac source) (14). Patients were excluded for any of
the following: ST-segment elevation myocardial infarction
(STEMI), a clear cause other than ACS for the symptoms
(e.g., examination findings of varicella zoster), inability to
provide informed consent, staff considered recruitment to be
inappropriate (e.g., receiving palliative treatment), transfer
from another hospital, pregnancy, previous enrollment, or
inability to be contacted after discharge. Perceived high risk
was not used as an exclusion criterion. Patients were
managed according to local hospital protocols, including
blood draws for cTnI measurement at presentation, and
then 6 to 12 h afterwards in compliance with international
guidelines (6,14). Christchurch Hospital used the Abbott
ARCHITECT cTnI assay (Abbott, Inc., Chicago, Illinois),
which has a detection limit of 0.01 /l, 99th percentile of
.028 /l, 10% coefficient of variation of 0.032 /l, and a
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risbane and Women’s Hospital used the DxI Access Accu
TnI assay (Beckman Coulter, Chaska, Minnesota), which
as a detection limit of 0.01 /l, 99th percentile of 0.04 /l,
10% coefficient of variation of 0.06 /l, and a decision
utoff, as per manufacturer, of0.04 /l. Following Federal
rug Authority concerns about results consistency between
xI analyzers for measurement of the Beckman assay, a
ocal reassessment was performed in Brisbane that showed
nly a 5% bias between the 2 local DxI analyzers. Long-
erm imprecision at the 99th percentile has been 13% to
4%. After assessment of local data, there has been no
arket withdrawal in Australasia. In both centers, results
or clinical use and outcomes adjudication were rounded to
decimal places.
Data were collected prospectively using a published data
ictionary (15). Nursing staff collected the demographic and
linical data from patients, supervised ECG testing, and
rew blood samples for cTnI testing. If a patient was unsure
f an answer to a question (e.g., history of hypertension), a
esponse of “No” was recorded. Patients were followed up to
etermine the occurrence of MACEs within 30 days of
resentation, at 45 days, and after 1 year using all of:
) telephone contact by research staff; 2) review of patients’
ospital notes; and 3) a national health events search (which
dentifies any death). Data were also recorded regarding the use
f further testing for ACS (e.g., stress testing or imaging) and
nterventions (therapeutic or procedural) within 30 days. The
entre for Clinical Research Excellence, Monash University,
elbourne, Australia, independently undertook data coordi-
ation, monitoring, analysis, and source verification.
ndex test. The predefined ADP under investigation con-
isted of a TIMI risk score of 0 at presentation (16), no
schemic changes on the initial ECG (i.e., not known to be
re-existing), and central laboratory cTnI concentrations (at
and 2 h after arrival) below the institutional cutoff used to
ndicate troponin elevation (Table 1). For a patient to be
dentified as low risk, all parameters in the ADP had to be
egative.
Patients with ischemic ECG changes and no evidence
hat they were pre-existing, were defined as high risk. ECG
hanges were defined as ST-segment depression of at least
.05 mV in 2 contiguous leads (including reciprocal
hanges), T-wave inversion of at least 0.1 mV, or Q waves
30 ms in width and 0.1 mV in depth in at least 2
ontiguous leads (15,17–19). Patients with other abnormal
CG findings (e.g., pacing artifact and left bundle branch
lock) that were present on pre-existing ECGs were not
efined as high risk.
Central laboratory cTnI concentrations (at 0 and 2 h after
rrival) above the institutional cutoff were used to indicate
TnI elevation. The same troponin assays and cutoffs were
sed to indicate cTnI elevation as for standard care at each
nstitution (as described previously).
eference standard. The primary endpoint was a compositef MACEs that occurred within 30 days after first presentation cincluding the initial hospital attendance). An adverse event
ncluded: death (unless clearly noncardiac), cardiac arrest,
mergency revascularization procedure, cardiogenic shock,
entricular arrhythmia needing intervention, high-degree
trioventricular block needing intervention, and acute myocar-
ial infarction (AMI) (Online Table 1). AMI was classified
sing the global taskforce recommendations requiring
vidence of myocardial necrosis together with clinical
vidence of myocardial ischemia (ischemic symptoms,
CG changes, or imaging evidence) (8). Necrosis was
iagnosed on the basis of a rising or falling pattern (a
elta of 20% was used) of the laboratory troponin
oncentrations, with at least 1 value above the decision
utpoint (99th percentile, at a level of assay imprecision
ear 10%). The cTnI results from blood draws at presenta-
ion, and after 6 to 12 h (i.e., from routine care) were used
or determination of necrosis. If the cTnI concentration was
levated, but a 20% rise or fall was recorded, then other
auses of a raised troponin concentration were actively
ursued by the adjudicators. If no clear alternative cause of
he troponin rise was evident, and if the clinical presentation
as suggestive of an ACS, an adjudicated diagnosis of AMI
as decided.
tatistical analysis. Baseline characteristics of the partici-
ants were analyzed with conventional group descriptive sta-
istics. For continuous variables, mean  SD were calculated,
hereas for categorical data, the proportions in each of the
DP positive and negative groups were reported. The sensi-
ivity, specificity, and positive and negative predictive values for
ierarchical primary and secondary events were generated
sing chi-square analyses for the ADP as a whole and its
onstituents individually or in combination. Sensitivities were
The ADAPT ADPTable 1 The ADAPT ADP
All parameters had to be negative for the ADP to be considered negative and for
the patient to be identified as low-risk
1. cTnI level at 0 and 2 h below institutional cutoff for an elevated troponin
concentration
2. No new ischemic changes on the initial ECG
3. TIMI score  0 (16)
a. Age 65 yrs
b. Three or more risk factors for coronary artery disease:
(family history of coronary artery disease, hypertension,
hypercholesterolaemia, diabetes, or being a current smoker)
c. Use of aspirin in the past 7 days
d. Significant coronary stenosis (e.g., previous coronary stenosis 50%)
e. Severe angina (e.g., 2 angina events in past 24 h or persisting
discomfort)
f. ST-segment deviation of 0.05 mV on first ECG
g. Increased troponin and/or creatine kinase-MB blood tests
(during assessment*)
*The results of the 0-h cardiac troponin-I (cTnI) were used for calculation of the Thrombolysis In
Myocardial Infarction (TIMI) score in this study, which is a modification from the original published
score. This score parameter and that of ST-segment deviation are effectively redundant in the
ADAPT accelerated diagnostic protocol (ADP) because of the broader cTnI and electrocardiographic
(ECG) criteria (1 and 2).ompared using the McNemar test.
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Patient characteristics. There were 1,975 consenting, eli-
ible patients suitable for analysis (Fig. 1). No patients were
ost to 30-day follow-up. Participants were predominantly
aucasian, older men who commonly had risk factors for
oronary artery disease; the cohort had a significant rate of
nown coronary artery disease (Table 2).
A total of 302 patients (15.3%) had a primary outcome
vent within 30 days, with most occurring within the first
0 days. The majority of these events (15.1%) were
yocardial infarctions (Table 3). The ADP identified
92 patients (20%) as low risk of a MACE within 30 days
Table 4).
iagnostic accuracy. Table 5 presents the statistical anal-
sis of the ADP and its parameters for predicting
ACEs within 30 days. Only 1 (0.25%) patient, classi-
ed as low risk by the ADP, had a MACE during initial
ospital attendance and follow-up. This patient was a
2-year-old Caucasian male who presented after 3.5 h of
hest pain. He was previously healthy, with no risk
actors for ischemic heart disease. He had a normal ECG
nd his Abbott troponin I was 0.01 g/l at 0 h, 0.03
Figure 1 Participant Recruitment Flowchart
The 193 patients eligible, but not recruited, were similar in age, gender, and risk
and no patients were lost to follow-up. ADP  accelerated diagnostic protocol; MAg/l at 2 h, and 16.8 g/l after 12 h. He underwent [ngiography and stenting for right coronary and circum-
ex artery stenosis. The patient had no further cardiac
roblems during 1 year of follow-up.
A secondary analysis using a TIMI score of 0 or 1 (as
pposed to TIMI 0) in the ADP resulted in 38.4% of
atients being categorized as low risk, but with 9 false
egative results for the primary outcome, giving a sensi-
ivity of 97.0%, negative predictive value of 98.8%,
pecificity of 44.8%, and positive predictive value of
4.1%.
Individual diagnostic parameters were not as effective at
dentifying patients who had a MACE compared with
hen these parameters were used together (Tables 4 and 5).
he combination of TIMI score and ECG without 0- and
-h troponin failed to identify 5 patients with a MACE at
0 days. Using the ADP, 4 of these 5 patients were correctly
dentified with a reduction in the number of false negatives
o 1 (Fig. 2). The ADP identified a larger proportion of
atients as low risk in participants presenting early after the
nset of symptoms (0 to 3 h) than among those presenting
ater (Online Table 1).
The majority of ADP negative patients (316 of 392
(p  0.05 for all). The 30-day follow-up included initial hospital attendance,
major adverse coronary event(s); TIMI  Thrombolysis In Myocardial Infarction.factors
CE 74.1%]) had further investigations within 30 days, and most of
Data m
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during the initial hospital attendance (88.0%). Investigations
generally occurred within a median timeframe of approxi-
mately 7 days (Online Table 2a). Therapeutic and procedural
interventions occurred in 18.3% and 2.0% of ADP negative
patients, respectively (Online Table 2b).
Demographics: Participant CharacteristicsTable 2 Demographics: Participant Charact
Characteristics (N
Demographics
Age, yrs 60.4
Sex (% male) 60.0
Ethnicity*
Caucasian 89.8
Maori 1.7
Aboriginal 0.8
Indian 0.9
Chinese 0.2
Other 6.8
Risk factors
Hypertension 52.1
Diabetes 14.4
Dyslipidemia 51.1
Smoking
Previous smoker 41.7
Current smoker 18.9
Family history of coronary artery disease 53.5
Medical history
Angina 33.8
Coronary artery disease 21.0
Acute myocardial infarction 23.3
Revascularization 17.3
Congestive heart failure 7.9
Stroke 9.6
Coronary artery bypass graft 8.7
Arrhythmia 6.1
Length of initial hospital attendance (h)
Median 31.3
Mean 81.8
Values are mean  SD, % (n), or median (interquartile range [IQR]). *
by patients.
Frequency and Type of Major Adverse Cardiac EDuring Initi l Hos ital Attendance or 30-Day FoTable 3 Frequency and Type of Major AdverDuring Initial Hospital Attendance o
Major Adverse Cardiac Event
No. of Events
(n  350)
Non–STEMI 273
STEMI 25
Emergency revascularization 26
Cardiovascular death 8
Ventricular arrhythmia 6
Cardiac arrest 3
Cardiogenic shock 4
High atrioventricular block 5ST-segment elevation myocardial infarction (STEMI) occurred after initial recr
attendance or 30-day follow-up.Discussion
This large 2-center Australasian study prospectively vali-
dated a 2-h ADP incorporating ECG, TIMI score, and
cTnI. With use of this ADP, a large group (20%) of patients
presenting with possible ACSs was identified as low risk
cs
) ADP Positive ADP Negative
9 63.2 14.8 49.4 9.2
5) 60.1 (951) 59.7 (234)
8) 90.3 (1,411) 87.5 (337)
1.9 (30) 1.0 (4)
0.8 (13) 0.8 (3)
0.8 (13) 1.0 (4)
0.2 (3) 0 (0)
) 6.0 (92) 9.6 (37)
9) 59.0 (934) 24.2 (95)
) 17.4 (276) 2.3 (9)
9) 57.5 (907) 26.1 (102)
) 43.5 (688) 34.5 (135)
) 18.3 (289) 21.7 (85)
6) 55.4 (874) 46.4 (182)
) 41.5 (657) 2.8 (11)
) 26.2 (414) 0.3 (1)
) 29.1 (461) 0 (0)
) 21.7 (341) 0 (0)
) 9.8 (155) 0.5 (2)
) 11.6 (183) 1.8 (7)
) 10.9 (172) 0 (0)
) 7.4 (116) 1.3 (5)
6) 48.0 (24–120) 24.1 (11.3–28.1)
.2 93.1 270.8 34.8 48.2
issing in 28 patients. Values 100% due to multiple factors reported
prdiac Event
-Day Follow-Up
entage of Patients
o Had Event Type
(n  302)
Percentage Frequency of
Event Type of Total Patients
(N  1,975)
90.40 13.82
8.28 1.27
8.61 1.32
2.65 0.41
1.99 0.30
0.99 0.15
1.32 0.20
1.66 0.25
*eristi
Total
1,975
 14.
(1,18
(1,74
(34)
(16)
(17)
(3)
(129
(1,02
(285
(1,00
(823
(374
(1,05
(668
(415
(461
(341
(157
(190
(172
(121
(24–9
 245ventllow-Us Ca
r 30
Perc
Whuitment. 350 events occurred in 302 patients during initial hospital
d cTnI w
s
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Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8and suitable for outpatient care at a risk of 0.25% for a
short-term MACE. These patients could have been safely
discharged to outpatient follow-up many hours earlier than
what usually occurs in current practice. The reduction in
time required for observation for some patients through
application of this ADP could have significant benefits for
health services, even in those centers with chest pain
observation units. In the United States alone, 6 million
ED visits a year involve patients presenting with chest pain
(20). In centers with lower disease prevalence, such as in the
United States, it is likely that even more patients would be
suitable for discharge to outpatient care with this ADP,
which could potentially reduce extended observation in
millions of patients annually. In patients unsuitable for
outpatient follow-up, a negative ADP result could allow
earlier in-patient investigation and still reduce length of stay
in the hospital.
The new ADP has a very high sensitivity and negative
predictive value, and using a contemporary cTnI as the
single biomarker in the ADP doubled the proportion of
patients classified as low risk in comparison to the ASPECT
study (20% vs. 9.8%) (11). If the cutoff used to define an
elevated troponin had been the internationally recom-
Test Parameter Performance: Occurrence of Major Adverse CardiacFollow-Up According to the Results of Individual and Combination oTable 4 T st Para et r Performa : Occurre ce f Major AdvFollow-Up According to the Results of Individual and C
Test
Outcome
MACE No MACE Total
ECG* Tr
Positive 74 193 267 P
Negative 228‡ 1,480 1,708 N
Total 302 1,673 1,975 To
TIMI§ E
Positive 293 1,238 1,531 P
Negative 9‡ 435 444 N
Total 302 1,673 1,975 T
ECG  TIMI¶ A
Positive 297 1,280 1,577 P
Negative 5‡ 393 398 N
Total 302 1,673 1,975 T
*Electrocardiography (ECG) alone: any new ischemia was positive. †Any cardiac troponin-I (cTn
§Thrombolysis In Myocardial Infarction (TIMI) score of 1 was positive. TIMI used contemporary cT
ischemia on ECG or TIMI score1 was positive. #ADP was negative if TIMI score was 0 and ECG an
MACE  major adverse cardiac event.
Diagnostic Accuracy: Accuracy of cTnI, ECG, TIMI, and ADP for PreTable 5 Diagnostic Accuracy: Accuracy of cTnI, ECG, TIMI, and
ECG ECG* Troponin†
Sensitivity 24.5 (20.0–29.7) 87.4 (83.2–90.7)
Negative predictive value 86.7 (85.0–88.2) 97.6 (96.7–98.3)
Specificity 88.5 (86.8–89.9) 92.6 (91.2–93.7)
Positive predictive value 27.7 (22.7–33.4) 68.0 (63.2–72.5)
Negative likelihood ratio 0.85 (0.80–0.91) 0.14 (0.10–0.18)
Positive likelihood ratio 2.12 (1.67–2.70) 11.79 (9.90–14.05)
*ECG alone: any new ischemia was positive. †cTnI more than cutoff for an elevated troponin was po
on ECG was positive. §TIMI and ECG: TIMI score of 1 was positive and/or any new ischemia on
core was 1 or any other parameter was positive, then ADP was positive.
Abbreviations as in Table 4.mended value of greater than the 99th percentile (rather
than using the local institution’s cutoff rounded to 2 decimal
places), the sensitivity of this ADP would have been
unchanged (99.7%). Using such a cutoff would have iden-
tified 3 less patients (n  389; 19.7%) as low risk (Online
Table 3).
This study confirms that each of the components of the
ADP, including troponin, is needed to achieve sufficient
sensitivity to be used at an early timeframe after presenta-
tion (Table 4). A TIMI score equaling 0 within the ADP
resulted in a lower and more acceptable false negative rate
than when only troponins and ECG were used for the
prediction of 30-day MACEs (0.25% vs. 3.2%).
This study also demonstrates that central laboratory
troponin assays currently in use have sufficient sensitivity at
an early time point to negate the need for additional
biomarkers (such as myoglobin and creatine kinase-MB) as
components of the ADP. These other biomarkers do not
improve the sensitivity, and reduce the proportion of pa-
tients defined as low risk (due to a greater number of
patients with a positive biomarker result), as was shown in
the ASPECT study (11).
nts During Initial Hospital Attendance or 30-DayAccelerated Diagnostic Pro ocol Test ParametersCardiac Even s During Initial Hospital Attendance or 30-Day
nation of the Accelerated Diagnostic Protocol Test Parameters
Test
Outcome
MACE No MACE Total
†
264 124 388
38‡ 1,549 1,587
302 1,673 1,975
roponin
269 291 560
33‡ 1,382 1,415
302 1,673 1,975
G  TIMI*  troponin)#
301 1,282 1,583
1‡ 391 392
302 1,673 1,975
ter than the cutoff was positive. ‡Accelerated diagnostic protocol (ADP) false negative cases.
ECG result at 0 h. cTnI more than the cutoff or any new ischemia on ECG was positive. ¶Any new
ere all negative. If TIMI score was1 or any other parameter was positive, then ADP was positive.
ion of MACEfor Prediction of MACE
ponin and ECG‡ TIMI and ECG§ ADP (ECG TIMI  Troponin)
9.1 (85.1–92.1) 98.3 (96.2–99.3) 99.7 (98.1–99.9)
7.7 (96.7–98.3) 98.7 (97.1–99.5) 99.7 (98.6–100.0)
2.6 (80.7–84.3) 23.5 (21.5–25.6) 23.4 (21.4–25.5)
8.0 (43.9–52.2) 18.8 (17.0–20.8) 19.0 (17.2–21.0)
.13 (0.10–0.18) 0.07 (0.03–0.17) 0.01 (0.002–0.10)
.12 (4.58–5.72) 1.29 (1.25–1.33) 1.30 (1.27–1.34)
‡Troponin and ECG: cTnI more than cutoff value for an elevated troponin and/or any new ischemia
s positive. ADP was negative if TIMI score was 0 and ECG and troponin were all negative. If TIMIEvef theers
ombi
oponin
ositive
egative
tal
CG  t
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June 5, 2012:2091–8 Rapid Assessment of Possible Cardiac Chest PainThe results show that the ADP is sensitive for both early
and late presenters, identifying a greater proportion of
patients as low risk in early presenters. Thus, the ADP
could have the greatest impact in patients presenting within
3 h of symptom onset, the group in which the second
troponin sampling time point is usually most delayed.
Body et al. (21) described how a highly sensitive cTn
(HS-cTn) assay may allow early “rule-out” of AMI using a
blood test only on arrival. Their study utilized the assay level
of detection rather than the 99th percentile. Highly sensi-
tive assays are not yet widely available, but if prospectively
validated, then this approach may be important. However,
when early results are used in conjunction with the TIMI
risk score and ECG, sensitivity may not be significantly
improved and specificity may be reduced. It is not yet clear
how early after presentation we can rely on negative highly
sensitive troponin results alone without requiring other
clinical data such as the TIMI score. Further work is also
needed to guide the interpretation and management of the
increased number of patients with a positive troponin result
that occur using highly sensitive troponin assays. Other
biomarkers, such as copeptin and heart fatty acid binding
protein, may improve the baseline sensitivity for AMI;
however, their use as part of an ADP has not been reported
(22,23). The early identification of patients with AMI is
important, but identifying a true low-risk cohort must
involve the detection of those at risk of a broader group of
adverse events, in addition to AMI.
Study limitations. The applicability of the ADP is re-
stricted to the selected cohort of patients with chest dis-
Figure 2 ADP Component False Negatives
Occurrence of major adverse cardiac event during initial hospital attendance or
30-day follow-up in patients with negative results for individual and combina-
tions of diagnostic parameters (values refer to numbers of patients). ECG 
electrocardiography; other abbreviations as in Figure 1.comfort suggestive of ACSs that the attending physicianplanned to investigate. In particular, the inclusion of pre-
dominantly Caucasian patients may restrict the interna-
tional generalizability of these findings. Patients who pre-
sented with atypical symptoms without chest pain were not
included in this trial, and deciding when to investigate these
for an ACS remains a challenge.
The study was an observational study and not an inter-
vention study. Ideally, a randomized controlled trial of the
diagnostic protocol would now occur. However, in practice,
such studies are rare. As a result of the observational design,
most ADP negative patients had further investigations and
some treatments as in-patients (Online Tables 2a and 2b).
Hospital admission, investigation, and subsequent treat-
ment (e.g., revascularization, antiplatelet, or antithrombotic
therapy) were common and possibly secured better out-
comes. Thus, patients who are ADP negative require
further nonurgent follow-up investigations and possibly
treatment. In some health systems, it will be possible for
these investigations to occur rapidly on an outpatient basis,
and where this is not possible, a negative ADP result could
allow earlier progression to in-patient investigation and still
reduce length of stay in the hospital.
The sensitivity of the ADP appears to be high. HS-cTn
assays appear to detect and predict additional adverse
outcomes compared with conventional assays. It is possible
that if an HS-cTn assay was used as the reference standard
troponin at arrival and after 6 h, then this would lead to
a greater number of patients being classified as having a
non-STEMI and, therefore, maybe a lower sensitivity. This
potential limitation is always a possibility when changing
technology creates a more sensitive reference standard. It is
also possible that by using HS-cTn assays, some patients
with negative results may be able to avoid, or have less
extensive follow-up investigations after ED assessment than
occurred in this cohort of patients. This requires further
evaluation. The purpose of this study was to show that an
ADP could use the same 2 troponin assays as currently used
at our hospitals to identify a group of patients as very low
risk at an earlier time point than usual. The specificity
(23.5%) of our method might be regarded as a limitation,
but as a “rule-out” rather than a “rule-in” tool, this speci-
ficity is a significant improvement compared with other
pathways (11). Patients who are not low risk according to
the ADP should continue to be managed with existing
clinical care that involves extended observation or admis-
sion. A process yielding a higher specificity could discharge
a larger number of patients, but at the cost of an unaccept-
able drop in sensitivity. This is demonstrated by the im-
proved low-risk eligibility, but increase in false negative
cases that would occur by using a TIMI score of 0 or 1
within this ADP. The TIMI score was derived from a
high-risk in-patient population to predict the likelihood of
a MACE and to guide therapy, and not for this “rule-out”
purpose in a low-risk ED population. Yet to date, it is one
of the most validated ACS risk tools available.
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Rapid Assessment of Possible Cardiac Chest Pain June 5, 2012:2091–8Conclusions
A 2-h ADP using a central laboratory troponin as the sole
biomarker in conjunction with ECG and the TIMI risk
score identified a large group of patients suitable for safe
early discharge. These patients are at low risk of a
short-term MACE. They could therefore have rapid
discharge with early outpatient follow-up or proceed
more quickly to further in-patients tests, potentially
shortening hospital length of stay. The components
required for this strategy are already widely available;
therefore, rapid uptake of the ADP is possible by most
hospitals with the potential for immediate health service
benefit.
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